Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Innovation Council · Ended early

ATLAS The first broad-spectrum treatment against pandemic-prone flaviviral infections: Dengue, West-Nile and Zika

Coordinator
Protinhi BV, Netherlands
Runs
1 March 2023 to 31 August 2026
Status
Ended early
EU funding
€2.5m
Total cost
€14.5m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190197515

What the project is doing

In the project's own words, from its summary on CORDIS.

WHO, governments and health institutes are urgently seeking methods to prevent future catastrophic flavivirus outbreaks affecting millions (annually >40% of the global population at risk, resulting in ~395M infections, >25,000 deaths of which mainly children, 750.000 disability-adjusted life years and >9B direct & indirect costs). As there are no effective treatments or vaccines available, ATLAS will provide a breakthrough in broad-spectrum antivirals: the first-in-class drug to combat the global health emergency of flaviviral infections.

In the ATLAS project, Protinhi will finalize clinical trial-enabling studies and pharmaceutical development and obtain proof-of-concept in humans by conducting Phase I and Phase IIa clinical trials against the most common flavivirus: dengue. This will put the company in an excellent position to attract interest from pharmaceutical companies (e.g. Gilead, J&J, MSD) for a strategic partnership for late clinical development and commercialization.

Topics

Who is involved

OrganisationCityCountryRole
Protinhi BVNijmegenNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI